Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alzamend Neuro Inc
(NQ:
ALZN
)
1.250
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alzamend Neuro Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
August 30, 2023
From
Alzamend Neuro
Via
Business Wire
EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder
August 30, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-BD01, a Phase 2A study of AL001 for bipolar disorder.
Via
Benzinga
Exposures
Product Safety
Why Ault Alliance Are Rocketing Today
July 12, 2023
Ault Alliance Inc (AMEX: AULT) shares are trading exponentially higher by over 147% after the company stated that
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 15, 2023
Via
Benzinga
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
July 07, 2023
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.
Via
Benzinga
EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study
June 22, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has identified a maximum tolerated dose (MTD) for developing AL001 from a multiple-ascending dose study as assessed by an independent safety review committee.
Via
Benzinga
Why Yext Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
June 07, 2023
Gainers
Via
Benzinga
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
June 22, 2023
From
Alzamend Neuro
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
June 07, 2023
We're starting the day off right with a breakdown of the biggest pre-market stock movers worth reading about on Wednesday!
Via
InvestorPlace
Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference
June 13, 2023
From
Alzamend Neuro
Via
Business Wire
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
May 24, 2023
These biotech stocks with high return potential are poised to provide quick returns for investors who invest over the next year.
Via
InvestorPlace
3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year
May 11, 2023
These 3 penny stocks have 10X potential over the next twelve months, providing the right risk/reward bet for certain investors.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
April 12, 2023
Via
Benzinga
EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine
April 03, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) has initiated a Phase 1/2A trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of Alzheimer’s type.
Via
Benzinga
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 04, 2023
From
Ault Alliance, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial
March 22, 2023
Alzamend Neuro Inc (NASDAQ: ALZN) announced it had completed the clinical portion of its Phase 2A multiple ascending dose (MAD) study of AL001 in subjects with dementia related to Alzheimer’s.
Via
Benzinga
Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
March 06, 2023
Gainers Secoo Holding Limited (NASDAQ: SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday.
Via
Benzinga
KILL Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 03, 2023
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 14, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 10, 2023
Via
Benzinga
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
April 03, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 28, 2022
Via
Benzinga
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
March 22, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia
December 28, 2022
Alzamend Neuro Inc (NASDAQ: ALZN) has partnered with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase 1/2A trial of ALZN002.
Via
Benzinga
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
March 16, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
SEC Goes After 'MrZackMorris, 'Stock Sniper' For Alleged Fraud
December 14, 2022
Eight people connected to Atlas Trading, a Discord-based community, have been named in a complaint filed by the Securities and Exchange Commission (SEC). Co-founders of the forum, podcasters, and...
Via
Benzinga
Alzamend Neuro to Present at Sequire Biotechnology Conference
January 26, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
January 04, 2023
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type
December 28, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
December 23, 2022
OnFriday, 143 stocks hit new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.